Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing Ads in US Magazines

Arena Pharma

today provided an update on Eisai Inc.'s marketing activities for BELVIQ^® (lorcaserin HCl) as the US launch campaign enters its consumer phase. Beginning this month, full-page announcements communicating the availability of BELVIQ are being placed in major US magazines, including O, The Oprah Magazine. These announcements are intended to educate consumers about BELVIQ as a treatment option for weight loss and weight maintenance. In addition, Eisai recently launched the BELIEVE EVERYDAY SUPPORT^SM program to provide comprehensive support and savings for patients treated with BELVIQ. Patients can enroll in the program at BelieveSupport.com. For Eisai's announcement with additional details about the program, click here. "Patient awareness and education about treatment options is an important component of the patient/physician relationship," said Jack Lief, Arena's President and Chief Executive Officer. "Eisai's consumer-focused efforts will complement their comprehensive healthcare professional education initiatives already underway." Eisai is responsible for the marketing and distribution of BELVIQ in the United States under its agreement with Arena.